Smithfield Trust Co Buys 96 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Smithfield Trust Co raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,048 shares of the medical research company’s stock after buying an additional 96 shares during the quarter. Smithfield Trust Co’s holdings in Thermo Fisher Scientific were worth $3,731,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Integrated Investment Consultants LLC increased its holdings in Thermo Fisher Scientific by 34.2% during the third quarter. Integrated Investment Consultants LLC now owns 1,009 shares of the medical research company’s stock worth $624,000 after buying an additional 257 shares during the last quarter. German American Bancorp Inc. increased its holdings in Thermo Fisher Scientific by 10.0% during the third quarter. German American Bancorp Inc. now owns 10,188 shares of the medical research company’s stock worth $6,302,000 after buying an additional 927 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new position in Thermo Fisher Scientific during the third quarter worth $235,000. Intech Investment Management LLC increased its holdings in Thermo Fisher Scientific by 8.8% during the third quarter. Intech Investment Management LLC now owns 3,417 shares of the medical research company’s stock worth $2,114,000 after buying an additional 275 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Thermo Fisher Scientific by 4.5% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 180,801 shares of the medical research company’s stock valued at $111,838,000 after purchasing an additional 7,727 shares during the period. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on TMO. Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Stifel Nicolaus lowered their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Raymond James increased their price target on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Finally, Royal Bank of Canada lowered their target price on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $649.33.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 9,000 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $552.86, for a total value of $4,975,740.00. Following the transaction, the chief executive officer now directly owns 14,608 shares in the company, valued at $8,076,178.88. The trade was a 38.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the sale, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 37,150 shares of company stock worth $20,651,865. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

TMO stock opened at $512.86 on Thursday. The firm has a market cap of $196.17 billion, a price-to-earnings ratio of 32.15, a PEG ratio of 3.37 and a beta of 0.79. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12-month low of $476.45 and a 12-month high of $627.88. The company’s fifty day simple moving average is $579.63 and its 200 day simple moving average is $580.98.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business’s revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.69 earnings per share. On average, analysts expect that Thermo Fisher Scientific Inc. will post 21.67 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.30%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.